These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25487755)

  • 21. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma.
    Lee SD; Kim SH; Kim YK; Kim C; Kim SK; Han SS; Park SJ
    Transpl Int; 2013 Jan; 26(1):50-60. PubMed ID: 23106431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in rat models with hepatocellular carcinoma with liver cirrhosis.
    Park SI; Lee JH; Ham HJ; Jung YJ; Park MS; Lee J; Maeng LS; Chung YA; Jang KS
    Biomed Mater Eng; 2015; 26 Suppl 1():S1669-76. PubMed ID: 26405933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT.
    Kim HO; Kim JS; Shin YM; Ryu JS; Lee YS; Lee SG
    J Nucl Med; 2010 Dec; 51(12):1849-56. PubMed ID: 21098794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
    Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
    Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis of Hepatocellular Carcinoma Using C11 Choline PET/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT.
    Chotipanich C; Kunawudhi A; Promteangtrong C; Tungsuppawattanakit P; Sricharunrat T; Wongsa P
    Asian Pac J Cancer Prev; 2016; 17(7):3569-73. PubMed ID: 27510010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma.
    Nakajima R; Abe K; Kondo T; Tanabe K; Sakai S
    Eur Radiol; 2016 Jun; 26(6):1852-62. PubMed ID: 26403580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection.
    Fartoux L; Balogova S; Nataf V; Kerrou K; Huchet V; Rosmorduc O; Talbot JN
    Nucl Med Commun; 2012 Jul; 33(7):757-65. PubMed ID: 22504293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic performance of
    Basha MAA; Hamed MAG; Refaat R; AlAzzazy MZ; Bessar MA; Mohamed EM; Ahmed AF; Tantawy HF; Altaher KM; Obaya AA; Afifi AHM
    Jpn J Radiol; 2018 Jun; 36(6):382-393. PubMed ID: 29671193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
    Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S
    J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study.
    Lee JR; Kim JS; Roh JL; Lee JH; Baek JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Radiology; 2015 Mar; 274(3):764-71. PubMed ID: 25405771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficiency of whole-body 18F-FDG PET CT in detecting the cause of rising serum AFP level in post-therapeutic follow-up for HCC patients.
    Ali SA; Amin DH; Abdelkhalek YI
    Jpn J Radiol; 2020 May; 38(5):472-479. PubMed ID: 32078123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary.
    Wang G; Wu Y; Zhang W; Li J; Wu P; Xie C
    J Med Imaging Radiat Oncol; 2013 Feb; 57(1):65-71. PubMed ID: 23374557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
    Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S
    Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients.
    Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Seki S; Yui M; Yamagata H; Aoyagi K; Matsumoto S; Sugimura K
    Radiology; 2015 Jun; 275(3):849-61. PubMed ID: 25584709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies.
    Baek S; Mueller A; Lim YS; Lee HC; Lee YJ; Gong G; Kim JS; Ryu JS; Oh SJ; Lee SJ; Bacher-Stier C; Fels L; Koglin N; Schatz CA; Dinkelborg LM; Moon DH
    J Nucl Med; 2013 Jan; 54(1):117-23. PubMed ID: 23232273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT.
    Ng SH; Chan SC; Yen TC; Liao CT; Chang JT; Ko SF; Wang HM; Lin CY; Chang KP; Lin YC
    Eur Radiol; 2010 Sep; 20(9):2229-40. PubMed ID: 20393714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis.
    Lin CY; Chen JH; Liang JA; Lin CC; Jeng LB; Kao CH
    Eur J Radiol; 2012 Sep; 81(9):2417-22. PubMed ID: 21899970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of patients with hepatocellular carcinomas using [(11)C]acetate and [(18)F]FDG PET/CT: A preliminary study.
    Hwang KH; Choi DJ; Lee SY; Lee MK; Choe W
    Appl Radiat Isot; 2009; 67(7-8):1195-8. PubMed ID: 19342249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.